3 Drugs Stocks Pushing The Industry Higher

Editor's Note: Any reference to TheStreet Ratings and its underlying recommendation does not reflect the opinion of TheStreet, Inc. or any of its contributors including Jim Cramer or Stephanie Link.

One out of the three major indices are trading lower today with the Dow Jones Industrial Average ( ^DJI) trading up 78 points (0.5%) at 16,105 as of Friday, Feb. 14, 2014, 11:55 AM ET. The NYSE advances/declines ratio sits at 1,755 issues advancing vs. 1,149 declining with 181 unchanged.

The Drugs industry currently sits down 0.6% versus the S&P 500, which is up 0.3%. Top gainers within the industry include Bristol-Myers Squibb Company ( BMY), up 1.4%, Eli Lilly and Company ( LLY), up 0.7% and Pfizer ( PFE), up 0.5%. On the negative front, top decliners within the industry include Incyte ( INCY), down 3.5%, Regeneron Pharmaceuticals ( REGN), down 2.1%, Valeant Pharmaceuticals International ( VRX), down 1.3%, Allergan ( AGN), down 0.7% and Celgene Corporation ( CELG), down 0.6%.

TheStreet would like to highlight 3 stocks pushing the industry higher today:

3. Novartis ( NVS) is one of the companies pushing the Drugs industry higher today. As of noon trading, Novartis is up $0.51 (0.6%) to $82.79 on heavy volume. Thus far, 1.4 million shares of Novartis exchanged hands as compared to its average daily volume of 1.5 million shares. The stock has ranged in price between $82.49-$82.92 after having opened the day at $82.56 as compared to the previous trading day's close of $82.28.

Its Pharmaceuticals division offers patented prescription medicines in various therapeutic areas, including oncology; primary care and established medicines; specialty care, such as ophthalmology, neuroscience, integrated hospital care, and critical care; and cardiovascular and metabolism. Novartis has a market cap of $198.6 billion and is part of the health care sector. Shares are up 2.4% year-to-date as of the close of trading on Thursday. Currently there are 4 analysts who rate Novartis a buy, no analysts rate it a sell, and 3 rate it a hold.

TheStreet Ratings rates Novartis as a buy. The company's strengths can be seen in multiple areas, such as its increase in stock price during the past year, revenue growth, reasonable valuation levels, largely solid financial position with reasonable debt levels by most measures and expanding profit margins. We feel these strengths outweigh the fact that the company has had somewhat disappointing return on equity. Get the full Novartis Ratings Report now.

3x UPSIDE POTENTIAL: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12 months. Learn more.

2. As of noon trading, GlaxoSmithKline ( GSK) is up $0.66 (1.2%) to $55.72 on light volume. Thus far, 732,509 shares of GlaxoSmithKline exchanged hands as compared to its average daily volume of 2.4 million shares. The stock has ranged in price between $55.38-$55.80 after having opened the day at $55.48 as compared to the previous trading day's close of $55.06.

GlaxoSmithKline plc manufactures and markets pharmaceutical products, over-the-counter medicines, and health-related consumer products worldwide. GlaxoSmithKline has a market cap of $133.0 billion and is part of the health care sector. Shares are up 2.7% year-to-date as of the close of trading on Thursday. Currently there is 1 analyst who rates GlaxoSmithKline a buy, no analysts rate it a sell, and 7 rate it a hold.

TheStreet Ratings rates GlaxoSmithKline as a buy. The company's strengths can be seen in multiple areas, such as its revenue growth, notable return on equity, increase in stock price during the past year, impressive record of earnings per share growth and compelling growth in net income. We feel these strengths outweigh the fact that the company has had generally high debt management risk by most measures that we evaluated. Get the full GlaxoSmithKline Ratings Report now.

3x UPSIDE POTENTIAL: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12 months. Learn more.

1. As of noon trading, Teva Pharmaceutical Industries ( TEVA) is up $0.46 (1.1%) to $44.32 on light volume. Thus far, 1.1 million shares of Teva Pharmaceutical Industries exchanged hands as compared to its average daily volume of 6.1 million shares. The stock has ranged in price between $43.87-$44.55 after having opened the day at $43.90 as compared to the previous trading day's close of $43.85.

Teva Pharmaceutical Industries Limited develops, manufactures, markets, and distributes pharmaceutical products worldwide. Teva Pharmaceutical Industries has a market cap of $41.7 billion and is part of the health care sector. Shares are up 9.4% year-to-date as of the close of trading on Thursday. Currently there are 5 analysts who rate Teva Pharmaceutical Industries a buy, 3 analysts rate it a sell, and 10 rate it a hold.

TheStreet Ratings rates Teva Pharmaceutical Industries as a buy. The company's strengths can be seen in multiple areas, such as its increase in net income, revenue growth, largely solid financial position with reasonable debt levels by most measures, increase in stock price during the past year and growth in earnings per share. We feel these strengths outweigh the fact that the company has had somewhat disappointing return on equity. Get the full Teva Pharmaceutical Industries Ratings Report now.

3x UPSIDE POTENTIAL: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12 months. Learn more.

If you are interested in one of these 3 stocks, ETFs may be of interest. Investors who are bullish on the drugs industry could consider SPDR S&P Pharmaceuticals ETF ( XPH) while those bearish on the drugs industry could consider ProShares UltraShort Nasdaq Biotech ( BIS).
null

If you liked this article you might like

Novartis May Sell U.S. Generic Pill Business Amid Industry Struggles

Novartis May Sell U.S. Generic Pill Business Amid Industry Struggles

Teva Shares Fall as FDA OKs Another Generic Version of Multiple Sclerosis Drug

Teva Shares Fall as FDA OKs Another Generic Version of Multiple Sclerosis Drug

Axovant Shares Crater as CEO and President Both Resign

Axovant Shares Crater as CEO and President Both Resign

Generic Drug Makers Hurt By Latest Federal Government Budget

Generic Drug Makers Hurt By Latest Federal Government Budget